Table 2

Comparative analysis of gene expression changes in primary and metastatic melanoma.
Gene Symbol
 Relative increase in gene expression
 Gene Symbol
 Relative decrease in gene expression

MIS to Thin
 Thin To IM
 IM to Thick
 Thick to Met
 MIS to Met
MIS to Thin
 Thin To IM
 IM to Thick
 Thick to Met
 MIS to Met
MAGEA2
 <2
 8.6
 9.4
 3.1
 30.7
 SPRR1A
 <2
 <2
 <2
 129.4
 239.3
MAGEA3
 <2
 8.1
 10.7
 3
 83.8
 SPRR1B
 <2
 <2
 <2
 52.8
 100.8
MAGE A6
 <2
 7.1
 9.8
 2.7
 103
 KRT16
 <2
 <2
 <2
 68.3
 195.5
MAGEA1,2
 <2
 2.5
 8.9
 2.6
 81.5
 KRT17
 <2
 2.6
 <2
 27.4
 57.6
MAGE A1
 <2
 <2
 11.1
 <2
 25.4
 KRT6B
 <2
 <2
 <2
 39.7
 100.9
MAGE A5
 <2
 2.2
 3.9
 <2
 11.7
 AQP3
 <2
 <2
 3.2
 6.1
 43.2
MMP19
 5.4
 <2
 <2
 <2
 7.4
 CD24
 <2
 <2
 2
 4.4
 18.7
PDGFRL
 22.3
 3.6
 <2
 <2
 6.3
 FLG
 <2
 <2
 3
 24.1
 140
C16orf34
 5.4
 <2
 <2
 <2
 18.5
 IVL
 <2
 2.2
 <2
 13.9
 84.1
CTH
 3.9
 <2
 <2
 <2
 8.8
 KLK7
 <2
 <2
 6.5
 8.9
 128
GPR19
 4.2
 <2
 3
 <2
 23.9
 LGALS7
 <2
 <2
 3.4
 17.3
 109.3
SPP1
 <2
 13.1
 <2
 <2
 44.9
 LOR
 <2
 <2
 2.4
 22.6
 120.4
HOXA10
 <2
 3.3
 <2
 <2
 3.8
 RAB25
 <2
 <2
 3.3
 10.3
 88.4
MMP14
 <2
 3.6
 <2
 2.1
 9
 SFN
 <2
 <2
 <2
 10.6
 24.2
AKT3
 <2
 <2
 7.5
 <2
 14.3
 C19orf33
 3.1
 <2
 4.6
 13.3
 220.3
BCL2A1
 <2
 2.2
 4.8
 <2
 18.7
 ASAH3
 <2
 <2
 25.9
 <2
 60
BIRC5
 <2
 <2
 3.7
 <2
 3.4
 KRT15
 <2
 <2
 27.1
 2.2
 104.9
BUB1
 <2
 <2
 9.4
 <2
 10.8
 ELOVL4
 <2
 2.3
 14.7
 <2
 41.9
CDC45L
 <2
 <2
 13
 <2
 9.1
 GATA3
 2.5
 <2
 14.3
 <2
 23.5
CDK2
 <2
 <2
 4.8
 <2
 8.4
 MUC15
 <2
 2.2
 11.9
 <2
 25
CSAG2
 <2
 <2
 19.6
 2.6
 54.5
 SCEL
 <2
 <2
 28.8
 <2
 71.8
DUSP4
 2
 <2
 5.7
 <2
 12.5
 TP73L
 <2
 <2
 5.5
 3.4
 41.2
DUSP6
 <2
 <2
 3.7
 <2
 10.5
 RORA
 <2
 <2
 6.2
 2.2
 26.6
GYPC
 <2
 <2
 12.2
 <2
 14.2
 POU2F3
 <2
 <2
 13.9
 2.2
 73.9
HEY1
 <2
 <2
 5.7
 <2
 9.3
 ICEBERG
 <2
 2.7
 6.7
 4.5
 32.3
KIFC1
 <2
 <2
 10.4
 <2
 16
 CASZ1
 <2
 4.8
 2.8
 <2
 12.3
PEG10
 <2
 2.4
 4.1
 <2
 11.3
 HR
 <2
 3.7
 <2
 <2
 7.7
RASGRF1
 <2
 <2
 5.1
 <2
 9.9
 TMPRSS4
 8.7
 <2
 <2
 3.1
 42
RGS20
 3.4
 <2
 9.2
 <2
 34.3
 STAR
 4.9
 <2
 <2
 <2
 11.1
SLC16A4
 <2
 <2
 4.4
 <2
 26.4
 ST7L
 4.3
 <2
 3.6
 <2
 8.4
SOX5
 <2
 <2
 12.3
 <2
 19.8
 LTB4R
 4
 <2
 2.3
 <2
 9.9
TRIM51
 <2
 3.1
 15.9
 <2
 63.6
 HAS3
 4.9
 <2
 <2
 2.5
 16.6
TYMS
 <2
 <2
 3.6
 <2
 4.7
 FGFR3
 3.9
 <2
 3.2
 <2
 7.6

NOTE: All annotated genes listed above with a < 2 indicates that any difference between tumors for each comparative analysis was less than 2-fold. Underlined numbers indicate the greatest change in gene expression across varying PCM tumor thickness for each gene. Abbreviations: MIS, melanoma-in-situ, Thin, thin melanomas < 1.0 mm in Breslow's thickness, I.M., intermediate thickness between 1–4 mm, with thick melanomas > 4 mm. PCM, primary cutaneous melanoma.

Riker et al. BMC Medical Genomics 2008 1:13   doi:10.1186/1755-8794-1-13